SCHEMBL3525829

SCHEMBL3525829

COc1[c]c2ccccc2c(OC)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 1/20 0.48
POLB P06746 2/20 0.39
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 1/20 0.34
IDO1 P14902 2/20 0.33
CYP2C9 P11712 1/20 0.33
RAD52 P43351 1/20 0.32
MCL1 Q07820 1/20 0.32
TUBB4A P04350 2/20 0.32
TUBB P07437 2/20 0.32
TUBA3C P0DPH7 2/20 0.32
TUBA1B P68363 2/20 0.32
TUBA4A P68366 2/20 0.32
TUBB4B P68371 2/20 0.32
TUBB3 Q13509 2/20 0.32
TUBB2A Q13885 2/20 0.32
TUBB8 Q3ZCM7 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2259297 0.83 ALDH1A1 (0.64) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL11202867 0.79 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL20694923 0.78 NQO1 (0.44) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL23071493 0.76 ALDH1A1 (0.48) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL16909846 0.72 NQO1 (0.46) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL8859782 0.70 ALDH1A1 (0.82) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL757747 0.70 KDM4E (0.82) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL16909758 0.69 HPGD (0.41) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL7430051 0.68 MPO (0.35) ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2
SCHEMBL8417546 0.68 KDM4E (0.54) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024135508-A1 COMPOUND, ORGANIC THIN FILM, PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR AND SOLID-STATE IMAGING DEVICE 三菱瓦斯化学株式会社 2024-06-27 WO disclosed
WO-2023167234-A1 COMPOUND, ORGANIC THIN FILM, PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR AND SOLID-STATE IMAGING DEVICE 三菱瓦斯化学株式会社 2023-09-07 WO disclosed
US-20220069354-A1 SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2022-03-03 US disclosed
EP-3904337-A1 SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL FUJIFILM Wako Pure Chemical Corporation (JP) 2021-11-03 EP disclosed
CN-108780924-B Electrolyte containing magnesium ions 富士胶片和光纯药株式会社 2021-09-24 CN disclosed
US-20210280870-A1 POSITIVE ELECTRODE ACTIVE MATERIAL FOR MAGNESIUM BATTERIES FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2021-09-09 US disclosed
EP-3832763-A1 POSITIVE ELECTRODE ACTIVE MATERIAL FOR MAGNESIUM BATTERIES FUJIFILM Wako Pure Chemical Corporation (JP) 2021-06-09 EP disclosed
CN-112236887-A Positive electrode active material for magnesium battery 富士胶片和光纯药株式会社 2021-01-15 CN disclosed
EP-3439097-B1 ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2020-12-30 EP disclosed
US-10727534-B2 Electrolyte solution containing magnesium ions FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2020-07-28 US disclosed
CN-1091432-A Can suppress the active peptide of hiv protease, its preparation with and medical use SANKYO CO (JP) 1994-08-31 CN disclosed
CN-1091128-A Piperidine derivative SANKYO CO (JP) 1994-08-24 CN disclosed
EP-0609058-A2 Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-08-03 EP disclosed
EP-0587311-A1 Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1994-03-16 EP disclosed
EP-0583971-A1 Piperidine derivatives SANKYO COMPANY LIMITED (JP) 1994-02-23 EP disclosed
EP-0283310-B1 N-BENZHYDRYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE Sankyo Company Limited (JP) 1993-05-26 EP disclosed
CN-1064683-A New beta-amino-alpha-hydroxycarboxylic acids and uses thereof SANKYO CO (JP) 1992-09-23 CN disclosed
EP-0498680-A1 New beta-amino-alpha-hydroxycarboxylic acids and their use Sankyo Company Limited (JP) 1992-08-12 EP disclosed
US-5028610-A Calcium Channel Blockers SANKYO COMPANY LIMITED (JP) 1991-07-02 US disclosed
EP-0283310-A1 N-Benzhydryl-substituted heterocyclic derivatives, their preparation and their use Sankyo Company Limited (JP) 1988-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10727534-B2 Electrolyte solution containing magnesium ions MLX, PRDX1, PRDX6 ALDH1A1 2396/4885KDM4E 1665/4885SMN1; SMN2 3634/4885
US-20220069354-A1 SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL SLC26A3, PRDX4, PRDX2 ALDH1A1 3074/4885KDM4E 2653/4885SMN1; SMN2 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.